Adlai Nortye Ltd.
NASDAQ:ANLBiotechnology
-$0.11 today
- Market cap
- $463.92M
- Beta
- 0.99
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.33
Volume 0.45M
Average 0.35M
ANL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Adlai Nortye Ltd.NASDAQ: ANL
Research & Development · Q2 FY2024 · quarter ended Jun 2024
Research & development declines year over year
Q2 FY2024 research & development of $13.01M fell 6.7% year over year, behind the -4.8% change in trailing-twelve-month research & development. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -15.5% a year.
Context
- Research & development amounted to 656.7% of revenue in FY2025.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -6.7% toward the trailing-twelve-month pace of -4.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 32.83M USD
- Year-over-year change
- -26.9%
- 4-year CAGR
- -6.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.83M | -26.9% |
| FY2024 | 2024-12-31 | 44.92M | -22.8% |
| FY2023 | 2023-12-31 | 58.15M | +6.7% |
| FY2022 | 2022-12-31 | 54.49M | +29.4% |
| FY2021 | 2021-12-31 | 42.11M | — |
Research & Development vs competitors
How ANL compares with its peers on the latest reported figures
- ANL's LTM Jun 2024 research & development of $56.93M is the 4th highest of the 7 companies compared; the peer median is $59.77M.
- Research & development amounts to 877.1% of revenue for ANL, versus a peer median of 75.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $128.85M | +18.2% | +9.4% | 75.8% | |
| LTM Mar 2026 | $123.67M | +33.3% | +31.4% | 249.4% | |
| LTM Mar 2026 | $82.1M | -9.4% | -6.8% | 290.9% | |
| LTM Jun 2024 | $56.93M | — | -15.5% | 877.1% | |
| LTM Mar 2026 | $37.44M | +64.5% | +11.3% | — | |
| LTM Mar 2026 | $23.92M | -1.0% | -9.4% | 32.9% | |
| FY2025 | $5.53M | -77.5% | -46.2% | 65.1% | |
| Peer median (excluding ANL) | $59.77M | +8.6% | +1.3% | 75.8% | |
Competitors are the stored peer set for ANL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 45.73M | 0 | 0 | 0 | 5M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 45.73M | 0 | 0 | 0 | 5M |
| Gross Margin | 100.0% | — | — | — | 100.0% |
| Research & Development | 42.11M | 54.49M | 58.15M | 44.92M | 32.83M |
| Selling, General & Admin | 12.45M | 12.43M | 14.82M | 9.44M | 7.79M |
| Operating Expenses | 54.37M | 67.27M | 72.55M | 52.93M | 40.7M |
| Depreciation & Amortization | 1.83M | 2.04M | 2.22M | 1.87M | 1.41M |
| EBITDA | (53.51M) | (56.32M) | (106.22M) | (48.06M) | (32.63M) |
| EBITDA Margin | -117.0% | — | — | — | -652.5% |
| Operating Income | (8.65M) | (67.27M) | (72.55M) | (52.93M) | (35.7M) |
| Operating Margin | -18.9% | — | — | — | -714.0% |
| Interest Income | 32K | 550K | 62K | 0 | 1K |
| Interest Expense | 1.34M | 433K | 791K | 1.94M | 1.49M |
| Other Income / Expenses | (48.03M) | 8.48M | (36.68M) | 1.06M | 170K |
| Income Before Tax | (56.68M) | (58.79M) | (109.23M) | (51.87M) | (35.53M) |
| Pre-Tax Margin | -124.0% | — | — | — | -710.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (56.68M) | (58.79M) | (109.23M) | (51.87M) | (35.53M) |
| Net Margin | -124.0% | — | — | — | -710.6% |
| EPS (Basic) | (6.66) | (6.93) | (15.42) | (4.89) | (3.33) |
| EPS (Diluted) | (6.66) | (6.93) | (15.42) | (4.89) | (3.33) |
| Weighted Avg Shares | 8.48M | 8.48M | 6.8M | 10.64M | 10.66M |
| Weighted Avg Shares (Diluted) | 8.48M | 8.48M | 6.8M | 10.64M | 10.66M |
Adlai Nortye Ltd.
NASDAQ:ANL
Intrinsic Alpha fair value
Locked
Current Price
$8.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.